EUVIMEDScopri EUVIMED
Crossref

From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?

Keith L. Carson

BioProcessing Journal · 2026-07-28 · 4

DOI: 10.12665/j124.carson ↗

At a glance

Journal article in BioProcessing Journal, published online on 2026-07-28. Written by Keith L. Carson.

AbstractDati bibliograficiCiteRelated studies

Abstract (original language)

I’ve seen little to tell me the major biopharma firms, or the larger supply firms, have learned anything. They’re stuck on the concepts of slashing vital resources—such as R&D and capacity—to “do deals” plus pay executive bonuses, investment bankers, and hordes of attorneys. As a result, we’ve seen a burgeoning of Business-to-Business (B2B) meetings where the talks are geared toward selling companies and acquisition services. So we continue to see these large firms hoarding cash, acquiring companies, and cutting strategic resources...

Cite

APA

Carson, K. L. (2026). From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?. BioProcessing Journal, 4. https://doi.org/10.12665/j124.carson

Vancouver

Carson KL. From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?. BioProcessing Journal. 2026:4. doi:10.12665/j124.carson

BibTeX
@article{Carson2026,
  author = {Carson, Keith L.},
  title = {From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?},
  journal = {BioProcessing Journal},
  year = {2026},
  pages = {4},
  doi = {10.12665/j124.carson}
}
Start for free →